The largest database of trusted experimental protocols

4 protocols using cc 115

1

Characterization of PIK3CA mutant cell lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
All cell lines were purchased from ATCC, DSMZ, JCRB or MD Anderson (Minna Lab), except for TM00244, which was purchased as a PDX from Jackson Labs. We generated a stable cell line from TM00244 and confirmed that it retained the PIK3CA mutation. All cell lines were maintained at 37°C in 5% CO2 in RPMI (Gibco; Catalog No. 11875–093), DMEM (Gibco; Catalog No. 11995–065), EMEM (ATCC; Catalog No. 30–2003), or McCoy’s 5A (ATCC; Catalog No. 30–2007) media and supplemented with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin, and 1% glutamine, except for RERFLCSQ1 and LOU-NH91, which were supplemented with 10% or 20% heat-inactivated fetal bovine serum, respectively. Cells were used within 20 passages from thaw for experiments and were STR profiled and routinely tested for mycoplasma (Lonza MycoAlert; Catalog No. LT07–703) every 6 months. For in vitro use, CC-115 (Selleck Chemicals; Catalog No. S7891) was dissolved in DMSO and clinical grade carboplatin (Rutgers Cancer Institute of New Jersey Pharmacy) was diluted in media. The molecular structure of CC-115 was previously published (31 (link)).
+ Open protocol
+ Expand
2

Protein and Inhibitor Sources for DNA-PK Research

Check if the same lab product or an alternative is used in the 5 most similar protocols
Recombinant human His-OCT4 protein from ProteinONE; Recombinant human
OCT4-mycDDK protein from OriGene; Recombinant human DNA-PK protein kinase from
Creative BioMart; DNA-PK inhibitor NU7441 (KU57788) and ATM kinase inhibitor
KU60019 from Tocris Bioscience; CC-115, a dual inhibitor of DNA-PK and mTOR,
from Selleckchem; M3814 (nedisertib) from Chemgood; ABT-199 (venetoclax) and
ABT-737 obtained from Abbott under MTA; ABT-263 (navitoclax) from
MedChemExpress; All oligonucleotides were from Integrated DNA Technologies
(IDT). Antibodies and their sources are included in Supplementary Methods.
+ Open protocol
+ Expand
3

Characterization of HNSCC and Skin Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
The HNSCC cell lines CAL33, UD-SCC-2, UM-SCC-47, and HSC4 were provided by Dr. Thorsten Rieckmann (University Medical Center Hamburg-Eppendorf, Germany) and cultivated in Dulbecco’s MEM (DMEM; Gibco, Waltham, MA, USA) supplemented with 10% FBS (Merck, Darmstadt, Germany) and 1% penicillin/streptomycin (Gibco, Waltham, MA, USA). CAL33 and HSC4 are HPV, while UM-SCC-47 and UD-SCC-2 are HPV+. SBLF7 and SBLF9 are normal human skin fibroblasts and were isolated from healthy donors by skin biopsy and subsequently cultivated with 15% FBS; 2% non-essential amino acids (NEA; Merck, Darmstadt, Germany); and 1% penicillin/streptomycin in F-12 medium (Gibco, Waltham, MA, USA). HaCaT are healthy human skin keratinocytes and were cultivated in Dulbecco’s Modified Eagle Medium with a glucose concentration of 4.5 g/L (DMEM (1X) + GlutaMAX − I; Gibco, Waltham, MA, USA) supplemented with 10% FBS and 1% penicillin/streptomycin. All cells were incubated at 37 °C in a humidified 5% CO2 atmosphere.
CC-115, AZD7648, and Sapanisertib (Selleckchem, Houston, TX, USA) were diluted in dimethyl sulfoxide (DMSO, Roth, Karlsruhe, Germany) and stored at −80 °C. The selected concentrations of KI were determined via a dilution series using CAL33 cells. Required aliquots were freshly thawed prior to each experiment.
+ Open protocol
+ Expand
4

Cell Viability Assay for Drug Synergy

Check if the same lab product or an alternative is used in the 5 most similar protocols
The cells were seeded in triplicate in clear, flat-bottomed 96-well plates in appropriate concentrations (MP46 and MM66: 4000 cells/well, MP38: 6000 cells/well, OMM2.3 and OMM2.5: 2000 cells/well, OMM1: 1500 cells/well). The next day, the medium was supplemented either with a single compound or a combination of the drugs. Five days later, the number of viable cells was determined using a CellTiter-Blue cell viability assay (Promega, Fitchburg, WI, USA). Everolimus, KU-0063794, OSI-906, CC-115, CRT0066101, and KU-57788 (NU7441) were purchased from Selleck Chemicals (Houston, TX, USA), LDN-193189 was obtained from Axon Medchem (Groningen, The Netherlands), and NU7026 was obtained from Cayman Chemical (Ann Arbor, MI, USA).
The synergistic score was calculated according to the Excess over Bliss model [42 (link)] using the formula:
where Fa is the fractional activity.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!